Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3500072 | 0.84 | MEN1 (0.40) | MPOBRD4KDM1AL3MBTL1 | |
| SCHEMBL3502308 | 0.82 | HDAC1 (0.38) | MPOESR2NPC1RAB9AKDM4E | |
| SCHEMBL3503719 | 0.81 | ESR2 (0.38) | MPOESR2NPC1RAB9ANR1H2 | |
| SCHEMBL4503093 | 0.76 | PTGER4 (0.42) | ESR2NR1H2CHRM4DRD2HTR7 | |
| SCHEMBL7659457 | 0.74 | NR1H2 (0.51) | ESR2NPC1RAB9ANR1H2KDM4E | |
| SCHEMBL6108617 | 0.74 | P2RX1 (0.50) | MPOESR2NPC1RAB9ABRD4 | |
| SCHEMBL16593635 | 0.74 | NOTUM (0.41) | MPOESR2NPC1RAB9ANR1H2 | |
| SCHEMBL15503181 | 0.74 | ESR2 (0.49) | ESR2NPC1RAB9ANR1H2CHRM4 | |
| SCHEMBL30918981 | 0.73 | MPO (0.41) | MPOESR2NPC1RAB9ANR1H2 | |
| SCHEMBL12489154 | 0.73 | ESR2 (0.54) | ESR2NR1H2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152165-A1 | CARBOXYLIC ACID DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20100152165-A1 | CARBOXYLIC ACID DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20100152165-A1 | CARBOXYLIC ACID DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2010-06-17 | — | — | US | disclosed |
| EP-2096109-A1 | CARBOXYLIC ACID DERIVATIVE | Astellas Pharma Inc. (JP) | 2009-09-02 | — | — | EP | disclosed |
| EP-2096109-A1 | CARBOXYLIC ACID DERIVATIVE | Astellas Pharma Inc. (JP) | 2009-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152165-A1 | CARBOXYLIC ACID DERIVATIVES | GPR119, GPR65, HCAR1 | MPO 4675/4885ESR2 791/4885NPC1 1572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.